The relation between observer-rated depressive symptoms and patient-rated quality of life after six weeks of antidepressant treatment: pooled patient-level analysis of mirtazapine trials
BJPsych Open · 2026-07 · 12 (4)
DOI: 10.1192/bjo.2026.12002 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJPsych Open, online erschienen am 09.06.2026. Verfasst von Helena Werin Sjögren und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, https://ror.org/01tm6cn81Institute of Neuroscience and Physiology, University of Gothenburg, Sweden. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
Background
The primary effect parameter in depression trials is usually a measure of depressive symptoms, e.g. the Hamilton Depression Rating Scale (HDRS). Such measures have been criticised for not covering patient-relevant domains, such as quality of life, and hence not accurately reflecting patient-experienced efficacy.
Aims
To investigate the relation between clinician-rated depressive symptoms and patient-reported quality of life measured by the Quality-of-Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF).
Method
We included data from six acute-phase trials ( n = 918) comparing mirtazapine to another antidepressant (amitriptyline, fluoxetine, paroxetine or venlafaxine) where both HDRS and Q-LES-Q-SF had been administered. No study included a placebo arm. Correlations between instruments (scales, subscales and items) were assessed after six weeks. Q-LES-Q-SF outcomes for participants who were in HDRS-defined remission were contrasted to those from participants with more severe depressive symptoms.
Results
Q-LES-Q-SF ratings correlated strongly with HDRS-17 ( r = −0.73, p < 0.0001) and HDRS-6 ( r = −0.72, p < 0.0001), but somewhat weaker to HDRS-11 ( r = −0.64, p < 0.0001). Depressed mood ( r = −0.66, p < 0.0001) and work and activities ( r = −0.65, p < 0.0001) showed the strongest item-level correlations to Q-LES-Q-SF. Participants in HDRS-remission had average Q-LES-Q-SF scores on the lower end of those reported by healthy controls, whereas patients with mild depressive symptoms (or worse) had average life-quality scores corresponding to severe impairment.
Conclusions
HDRS and Q-LES-Q-SF showed considerable agreement in depressed study participants treated with antidepressants, suggesting that HDRS meaningfully reflects patient-reported improvement.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, https://ror.org/01tm6cn81Institute of Neuroscience and Physiology, University of Gothenburg, Sweden.
- Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Sweden.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
- Department of Clinical Medicine, https://ror.org/01aj84f44Aarhus University, Denmark.
ORCID-Profile: Alexander Lisinski, Fredrik Hieronymus
Zitieren
APA
Sjögren, H. W., López, E., Lisinski, A., Landén, M., Lundberg, J., & Hieronymus, F. (2026). The relation between observer-rated depressive symptoms and patient-rated quality of life after six weeks of antidepressant treatment: pooled patient-level analysis of mirtazapine trials. BJPsych Open, 12(4). https://doi.org/10.1192/bjo.2026.12002
Vancouver
Sjögren HW, López E, Lisinski A, Landén M, Lundberg J, Hieronymus F. The relation between observer-rated depressive symptoms and patient-rated quality of life after six weeks of antidepressant treatment: pooled patient-level analysis of mirtazapine trials. BJPsych Open. 2026;12(4). doi:10.1192/bjo.2026.12002
BibTeX
@article{Sjgren2026,
author = {Sjögren, Helena Werin and López, Evana and Lisinski, Alexander and Landén, Mikael and Lundberg, Johan and Hieronymus, Fredrik},
title = {The relation between observer-rated depressive symptoms and patient-rated quality of life after six weeks of antidepressant treatment: pooled patient-level analysis of mirtazapine trials},
journal = {BJPsych Open},
year = {2026},
volume = {12},
number = {4},
doi = {10.1192/bjo.2026.12002}
}
EUVIMED